Fianlimab Biosimilar – Anti-LAG3, CD223 mAb – Research Grade

Description of Fianlimab Biosimilar - Anti-LAG3, CD223 mAb - Research Grade

Introduction

Fianlimab Biosimilar is a novel antibody that targets the protein LAG3, also known as CD223. This antibody has been developed as a biosimilar of the existing anti-LAG3 antibody, with the aim of providing a more affordable and accessible treatment option for patients. In this article, we will explore the structure, activity, and potential applications of Fianlimab Biosimilar as a therapeutic agent.

Structure of Fianlimab Biosimilar

Fianlimab Biosimilar is a monoclonal antibody, meaning it is derived from a single type of immune cell. It is a humanized antibody, which means that it has been modified to contain both human and non-human components. This modification is important as it reduces the risk of an immune response against the antibody when administered to patients.

The antibody has a Y-shaped structure, with two arms that can bind to the LAG3 protein. The binding site of Fianlimab Biosimilar is located on the variable region of the antibody, which is specifically designed to recognize and bind to LAG3 with high affinity.

Activity of Fianlimab Biosimilar

Fianlimab Biosimilar works by blocking the activity of LAG3, a protein found on the surface of immune cells. LAG3 is known to play a role in regulating the activity of T cells, a type of white blood cell that is crucial for the body’s immune response. When LAG3 is activated, it inhibits the function of T cells, leading to a weakened immune response.

By blocking LAG3, Fianlimab Biosimilar allows T cells to function more effectively, leading to a stronger immune response against cancer cells or other disease-causing agents. This activity of Fianlimab Biosimilar makes it a promising therapeutic agent for the treatment of various diseases, particularly cancer.

Potential Applications of Fianlimab Biosimilar

As a biosimilar of the existing anti-LAG3 antibody, Fianlimab Biosimilar is being developed for the treatment of various types of cancer. LAG3 has been found to be overexpressed in several types of cancer, including melanoma, lung cancer, and ovarian cancer. Therefore, by targeting LAG3, Fianlimab Biosimilar has the potential to be an effective treatment for these cancers.

Additionally, Fianlimab Biosimilar may also have applications in autoimmune diseases. LAG3 has been implicated in the development of autoimmune disorders, and by blocking its activity, Fianlimab Biosimilar may help in managing these conditions.

Conclusion

In summary, Fianlimab Biosimilar is a novel antibody that targets the protein LAG3. Its structure, as a humanized monoclonal antibody, allows for high affinity binding to LAG3. By blocking the activity of LAG3, Fianlimab Biosimilar has the potential to be an effective treatment for various types of cancer and autoimmune diseases. As research on this biosimilar continues, it may provide a more accessible and affordable option for patients in need of anti-LAG3 therapy.

SDS-PAGE for Fianlimab Biosimilar - Anti-LAG3, CD223 mAb

Fianlimab Biosimilar - Anti-LAG3, CD223 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.